📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company’s individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding GRDN

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Jim Simons Renaissance Technologies LLC	100.0K	$3.8M	0.01%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly used phrases like 'strong', 'raised guidance', 'confident', and provided specific financial figures (15% revenue growth, 12% resident count increase, etc.) while detailing acquisition and startup activities. The tone was assured and backed by data.

Q3 2025

Confident Specific

Management used strong language: 'another strong quarter', 'double-digit growth', 'raising full-year guidance', 'growing ever more confident' in offsetting headwinds. They provided specific figures and reiterated disciplined execution.

Q4 2025

Confident Specific

Management repeatedly used phrases like 'exceeded our expectations across the board', 'very strong quarter', 'ahead of plan' and cited specific metrics such as 13% organic revenue growth, 27% adjusted EBITDA growth, and 27% return on equity. They provided granular details on clinical interventions, vaccine clinic results, and margin expansion.

Q1 2026 latest

Confident Specific

Management used phrases like 'pleased to report solid results', 'performed in line with our expectations', and 'reinforcing the effectiveness of our approach' to convey controlled navigation of IRA headwinds. They gave specific numbers (60% branded price decline, $10M headwind offset, $3M discrete benefit) showing data-driven confidence.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis appears slightly stronger after this call. Guardian demonstrated its ability to offset a significant IRA headwind (60% price decline on affected branded drugs) through proactive payer negotiations and operational efficiency, delivering double-digit gross profit growth. The $3M discrete benefit partially boosted EBITDA but management transparently excluded it from underlying run-rate. Key watch items for next quarter: (1) whether the working capital drag from IRA normalizes as promised, (2) direction of fuel costs and its impact on margins, (3) pace of M&A closings given the robust pipeline, and (4) any updates on the Omnicare situation. The 14% market share in assisted living suggests ample organic runway, but margin expansion will depend on continued execution and cost discipline.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Guardian Pharmacy Q1 2026: 19% gross profit growth, raises EBITDA guidance despite IRA headwinds

Revenue & Profitability

Revenue for Q1 2026 was $336.6 million, up 2% year-over-year. Gross profit was $76 million, up 19% (14% excluding a $3 million discrete benefit). Adjusted EBITDA was $29.8 million, up 27%, with an 8.8% margin. Adjusted EPS was $0.29. Full-year adjusted EBITDA guidance was raised to $123-$127 million from $120-$124 million.

Outlook

Management sees continued pressure on peers from IRA unintended consequences and views near-term legislative relief, such as a dispensing fee for long-term care pharmacies, as uncertain. Industry occupancy was challenged in Q1 due to weather, but underlying demand from the aging population ('silver tsunami') remains intact. Fuel cost volatility and higher labor costs are potential headwinds.

Growth Drivers

Organic resident growth of 10% and script volume growth of 10% driven by strong fundamentals. M&A pipeline is robust; the company expects to maintain its historical acquisition pace. Expansion with national accounts remains a key driver. With only 14% market share in assisted living, there is significant white-space opportunity.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Reported gross margin was 22.7% (22% excluding discrete benefits). Adjusted EBITDA margin was 8.8% (8% excluding benefits). Acquisitions completed over the past two years dampen consolidated margins by approximately 80 basis points. The company is shifting towards a model where margin is more aligned with generic scripts (90/8 split), de-risking the business.

Key Risks

Key risks flagged include: ongoing IRA implementation complexities and payment delays; potential fuel cost headwinds of up to a few million dollars annually; higher labor costs from targeted hiring; uncertainty around near-term legislative relief; and timing of working capital normalization from IRA-related cash flow shifts.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Revenue grew 2% year-over-year in Q2 2026, with adjusted EBITDA up 19% and net income reaching $22.1 million. Full-year guidance was raised, reflecting strong organic growth and disciplined M&A, while IRA-related pricing reductions continue to impact reported revenue.

Q1 2026 Q1 2026 2026-05-06

Solid Q1 results with 2% revenue growth and 19% gross profit increase despite IRA headwinds. Updated adjusted EBITDA guidance to $123–$127 million, maintained revenue outlook, and continued robust M&A activity.

Q4 2025 Q4 2025 2026-03-11

Q4 and full-year 2025 results exceeded expectations, with 18% revenue growth and 27% adjusted EBITDA growth year-over-year. Raised 2026 EBITDA guidance to $120–$124 million, maintaining strong cash flow and robust M&A pipeline amid industry changes.

Q3 2025 Q3 2025 2025-11-10

Achieved 20% revenue growth and 19% adjusted EBITDA growth year-over-year, raising full-year guidance for both metrics. Recent acquisitions and organic growth drove results, with steady margins and strong cash generation supporting ongoing expansion.

Q2 2025 Q2 2025 2025-08-11

Q2 2025 saw double-digit growth in revenue, resident count, and adjusted EBITDA, with strong organic and acquisition-driven expansion. Guidance for full-year revenue and EBITDA was raised, while policy risks from the IRA and PBM negotiations are being proactively managed.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.